For research and educational purposes only. Not intended for human consumption.
CJC-1295 with DAC
Well Researched- •DAC technology: 6-8 day half-life confirmed
- •WADA prohibited substance status maintained
- •IGF-1 elevation studies updated
Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release
Overview
What is CJC-1295 with DAC?
CJC-1295 with DAC (Drug Affinity Complex) is a modified version of growth hormone releasing hormone (GHRH) engineered for extended duration. The addition of DAC technology extends the half-life to 6-8 days, providing continuous growth hormone elevation rather than pulsatile release. This long-acting formulation offers convenience but differs significantly from natural GH secretion patterns. Banned by WADA
Key Benefits
Convenient weekly dosing, sustained GH/IGF-1 elevation, significant body composition changes.
Mechanism of Action
DAC technology binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation.
Molecular Information
Pharmacokinetics
Research Indications
Sustained GH Elevation
Provides continuous growth hormone release for 6-8 days per injection.
IGF-1 Optimization
Significantly elevates IGF-1 levels for extended periods.
Convenience Protocol
Weekly dosing schedule ideal for simple administration.
Research Protocols
Disclaimer: Cycling (8-12 weeks on, 4-8 weeks off) is commonly discussed to help maintain pituitary sensitivity from continuous GHRH stimulation. Unlike the non-DAC version, a loading phase is generally not reported due to the long half-life.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Conservative Anti-Aging | 1mg | Once weekly | Subcutaneous |
| Standard Protocol | 2mg | Once weekly | Subcutaneous |
| Split Dosing | 1mg | Twice weekly (Mon/Thu) | Subcutaneous |
| Loading Protocol | 2mg first week, then 1mg | Weekly | Subcutaneous |
Timing: Due to long half-life, injection timing is flexible. Many prefer morning injections to monitor for side effects during the day.
Peptide Interactions
How to Reconstitute
Important: Always use bacteriostatic water (BAC). Sterile technique is essential.
Clean both vial tops with alcohol and let dry completely
For 2mg vial: Add 1mL bacteriostatic water (creates 2mg/mL concentration)
For 5mg vial: Add 2.5mL bacteriostatic water (creates 2mg/mL concentration)
Inject water very slowly to prevent foaming - DAC peptides foam easily
Let sit for 5 minutes before gently rolling to mix
Solution may appear slightly cloudy initially but should clear
Label with date and concentration immediately
Dosing Calculator
Calculate your injection volume with visual dosing guide
To obtain 250 mcg from this solution:
Draw 0.10 mL=10 units
(1 mL = 100 units on any insulin syringe)
Draw to this mark for 250 mcg
This calculator is for research purposes only. Always verify calculations and consult protocols.
Quality Indicators
High Purity Requirement
DAC peptides require >98% purity - impurities cause more side effects.
Proper DAC Labeling
Legitimate products clearly state 'with DAC' to distinguish from regular CJC-1295.
More Expensive than Non-DAC
DAC version costs 2-3x more due to complex manufacturing.
Foaming During Mixing
Normal for DAC peptides to foam - wait for foam to settle.
Extremely Cheap Pricing
If priced similar to non-DAC version, likely mislabeled or fake.
Clear Solution Immediately
Should be slightly cloudy initially - immediate clarity may indicate non-DAC.
What to Expect
- •Week 1: Possible water retention, improved sleep, increased appetite
- •Week 2-3: Noticeable recovery improvements, some report joint discomfort
- •Week 4-6: Visible body composition changes, increased vascularity
- •Week 6-8: Continued improvements but watch for desensitization signs
- •Post-cycle: Maintain most gains, IGF-1 returns to baseline in 2-3 weeks
Side Effects & Safety
Side Effects
- •Higher side effect incidence than pulsatile protocols
- •Common: Water retention, joint pain, carpal tunnel symptoms
- •Monitor for signs of excessive GH: jaw growth, hand/feet enlargement
- •Not suitable for those with diabetes or cancer history
- •May worsen sleep apnea in predisposed individuals
- •Regular IGF-1 monitoring recommended for long-term use
When to Stop
- •Signs of excessive GH (jaw/hand growth)
- •Severe water retention
- •Significant joint pain
- •Sleep apnea worsening
- •As directed by healthcare provider
References
3 StudiesDAC vs Non-DAC Pharmacokinetics (2015)
Human | Crossover design | 30 days each arm | 120-hour vs 30-minute half-life
DAC version showed 120-hour half-life versus 30-minute half-life of non-DAC, but non-DAC preserved more physiological GH patterns.
Long-term Effects on GH/IGF-1 Axis (2012)
Animal model | 6 months | Weekly dosing | Sustained IGF-1 elevation
Chronic administration led to sustained IGF-1 elevation but some evidence of reduced GH pulse amplitude, suggesting partial desensitization.
Dose-Response Relationship (2008)
Human | Multiple doses | 90 days | 48 subjects | Optimal 1-2mg weekly dosing
Established optimal dosing at 1-2mg weekly, showing dose-dependent IGF-1 increases but higher side effects above 2mg.
Quick Start Guide
Research Disclaimer
CJC-1295 with DAC is sold for laboratory research purposes only and is not intended for human or animal consumption. The information provided on this page is compiled from published research, veterinary studies, and anecdotal reports for educational purposes. This content does not constitute medical advice, diagnosis, or treatment recommendations. Any research involving CJC-1295 with DAC must comply with all applicable local, state, and federal regulations. BioInfinity Lab makes no claims regarding the safety or efficacy of CJC-1295 with DAC for any purpose. Consult qualified professionals for any research applications.